Publications en collaboration avec des chercheurs de Hospital Universitario de Salamanca (14)

2024

  1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

2014

  1. Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T cell blast crisis

    Cell Cycle, Vol. 13, Núm. 11, pp. 1717-1726

2012

  1. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma

    British Journal of Haematology, Vol. 158, Núm. 6, pp. 712-726

2011

  1. Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas

    PLoS ONE, Vol. 6, Núm. 9

2010

  1. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

    Blood, Vol. 116, Núm. 14, pp. 2531-2542

2004

  1. Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia

    Cancer Genetics and Cytogenetics, Vol. 153, Núm. 1, pp. 16-25

2003

  1. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study

    Leukemia, Vol. 17, Núm. 10, pp. 2016-2024

2001

  1. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracycline-based protocol. A report from the spanish group PETHEMA

    Haematologica, Vol. 86, Núm. 8, pp. 807-813

  2. Novel genomic imbalances in b-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics

    American Journal of Pathology, Vol. 158, Núm. 5, pp. 1843-1850